New pill-and-infusion combo targets rare lymphoma in early trial
NCT ID NCT06647732
First seen Jan 19, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This study tests whether combining two drugs—zanubrutinib (a pill) and rituximab (an infusion)—can shrink or control MALT lymphoma, a slow-growing cancer of the lymph nodes. About 42 adults with advanced or newly relapsed disease will receive the combo as their first systemic treatment. The goal is to see how many achieve complete remission and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 51000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.